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AbstrACt
Objective The role of vitamin K in the regulation of 
vascular calcification is established. However, the 
association of dietary vitamins K1 and K2 with risk of 
coronary heart disease (CHD) is inconclusive.
Design Prospective cohort study.
setting We followed participants in the community- based 
Hordaland Health Study from 1997 - 1999 through 2009 
to evaluate associations between intake of vitamin K and 
incident (new onset) CHD. Baseline diet was assessed by 
a past- year food frequency questionnaire. Energy- adjusted 
residuals of vitamin K1 and vitamin K2 intakes were 
categorised into quartiles.
Participants 2987 Norwegian men and women, age 
46–49 years.
Methods Information on incident CHD events was 
obtained from the nationwide Cardiovascular Disease in 
Norway (CVDNOR) Project. Multivariable Cox regression 
estimated HRs and 95% CIs with test for linear trends 
across quartiles. Analyses were adjusted for age, sex, total 
energy intake, physical activity, smoking and education. A 
third model further adjusted K1 intake for energy- adjusted 
fibre and folate, while K2 intake was adjusted for energy- 
adjusted saturated fatty acids and calcium.
results During a median follow- up time of 11 years, 
we documented 112 incident CHD cases. In the adjusted 
analyses, there was no association between intake of 
vitamin K1 and CHD (HR
Q4vsQ1 = 0.92 (95% CI 0.54 to 
1.57), p for trend 0.64), while there was a lower risk of 
CHD associated with higher intake of energy- adjusted 
vitamin K2 (HR
Q4vsQ1 = 0.52 (0.29 to 0.94), p for trend 
0.03). Further adjustment for potential dietary confounders 
did not materially change the association for K1, while the 
association for K2 was slightly attenuated (HR
Q4vsQ1 = 0.58 
(0.28 to 1.19)).
Conclusions A higher intake of vitamin K2 was 
associated with lower risk of CHD, while there was no 
association between intake of vitamin K1 and CHD.
trial registration number NCT03013725
IntrODuCtIOn
Vitamin K is a fat- soluble vitamin including 
vitamin K1 (K1; phylloquinone) from green 
leafy vegetables and vegetable oils as the 
main dietary sources, and vitamin K2 (K2; 
menaquinones) from dairy products, meat 
and egg yolk as the main dietary sources in 
Europe.1–3 K2 has a longer half- life in the 
circulation than K1.4 Both are absorbed 
from the small ileum and jejunum. K1 and 
K2 are incorporated into chylomicrons and 
delivered to the liver. K2 is also transported 
via low- density lipoprotein and high- density 
lipoprotein (HDL) particles to extrahepatic 
tissue.4 5
Vitamin K functions as a cofactor for the 
enzyme gamma- glutamyl carboxylase which 
converts protein- bound glutamate residues 
into gammacarboxyglutamate (Gla).6 7 Gla- 
containing proteins are involved in, for 
example, the coagulation of blood,8 inhi-
bition of arterial calcification (Matrix Gla 
Protein) and vascular smooth muscle cell 
apoptosis and movement that is considered 
protective against vascular injury (Gas-6).9 
Matrix Gla Protein is involved in both medial 
and intimal calcification, and low vitamin K 
status has been associated with both types 
of calcification.10–14 In addition, a study that 
examined the effect of warfarin (a vitamin 
K antagonist) on medial and intimal plaque 
strengths and limitations of this study
 ► The study had a long follow- up time with minimal 
competing risk from other causes of death.
 ► Linkage to a nationwide database assured complete 
cohort follow- up.
 ► We had information on history of coronary heart dis-
ease (CHD) at baseline which enabled us to evaluate 
incident (new onset) CHD.
 ► The Food Frequency Questionnaire was not validat-
ed for intake of vitamin K.
 ► It was not possible to differentiate the various sub-
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calcification in apoE−/− mice concluded that warfarin 
accelerates both medial and intimal calcification of 
atherosclerotic plaque.15 Patients with both medial and 
intimal calcification have a higher cardiovascular risk 
when compared with similar patients without calcifi-
cation.16 17 Therefore, an inverse association between 
vitamin K intake and coronary heart disease (CHD) 
could be expected. Results from observational studies 
on the association between intake of vitamin K and CHD 
are inconsistent.18–24 Among the identified studies, three 
found reduced risk of CHD in multivariable adjusted 
analyses at higher dietary K219 20 or K1.24
Nordic Nutrition Recommendations include a provi-
sional recommended intake of vitamin K of 1 µg/kg body 
weight per day,3 while adequate intake is 90 µg/day for 
women and 120 µg/day for men.25 However, these recom-
mendations may not be sufficient to attain complete 
carboxylation of extrahepatic vitamin K- dependent 
proteins.26 27
Given the limited number of epidemiological 
studies,18–24 and the fact that dietary vitamin K sources and 
content differ between countries,28–31 further research is 
warranted. The purpose of the current study was to eval-
uate the association between intake of both K1 and K2 
and subsequent CHD events among community- living 
middle- age adults in Norway.
subjeCts AnD MethODs
study population
The current study is a prospective, community- based 
cohort study of participants living in Hordaland County, 
Norway (known as The Hordaland Health Study (HUSK); 
https:// husk. w. uib. no/). The recruitment was based on a 
cohort from 1992 - 1993 (The Hordaland Homocysteine 
Study), where eligible subjects (Hordaland County resi-
dents born 1950–1951) were identified from the National 
Population Register on 31 December 1992.32 33 In 1997–
1999, all living Homocysteine Study cohort members 
born 1950–1951 and residing in the city of Bergen or 
the neighbouring suburban municipalities were invited 
to participate in HUSK. The baseline examinations were 
conducted during 1997–1999 as a collaboration between 
the National Health Screening Service (now The Norwe-
gian Institute of Public Health), The University of Bergen 
and local health services. Participation rate was 77%. 
Participants underwent a brief health examination and 
provided a non- fasting blood sample. Information on life-
style was collected via self- administered questionnaires. A 
semiquantitative Food Frequency Questionnaire (FFQ) 
was completed by 87% of the participants yielding 3107 
men and women age 47–49 years eligible for the current 
study.
We excluded from the analyses 27 men and 35 
women who reported extreme energy intakes (below 
the first percentile: <1125 kcal for men and <705 kcal 
for women; or above the 99th percentile: >4519 kcal for 
men and >3571 kcal for women). Further, we excluded 
27 participants (22 men and 5 women) who had prior 
CHD based on self- reported information and/or prior 
CHD hospitalisations during 1994–1999. Additionally, 
those with missing information on self- reported myocar-
dial infarction from the Homocysteine Study (1992–
1993; 4 men and 19 women) were excluded. Further, we 
excluded two participants (one man and one woman) 
who reported use of warfarin and six participants (two 
men and four women) with missing measurement on 
dietary vitamin K intake. The final study population thus 
included 1279 men and 1708 women.
Patient and public involvement
Participants were not involved in designing the research 
question, conducting the study, or in the interpretation, 
or writing of the results. There are no plans to involve 
participants or relevant patient communities in dissemi-
nation of results. Results are disseminated to study partic-
ipants via website (https:// husk. w. uib. no).
Dietary assessment
Information on food intake was obtained at baseline 
(1997–1999) using a slightly modified version of a previ-
ously described34 past- year 169- item semiquantitative 
FFQ. The FFQ was handed out on the health examination 
day, filled out at home and returned by mail to the HUSK 
project centre. The questionnaire included frequency 
alternatives (from once a month to several times per day), 
the number of units consumed and portion sizes (eg, 
slices, glasses, spoons) to capture the habitual diet during 
the past year. The dietary information presented includes 
individual food or beverage items, food groups and 
nutrient intakes. Daily nutrient intakes were computed 
from a database and software system developed at the 
Department of Nutrition, University of Oslo (KBS, V.3.2). 
The nutrient database is primarily based on the offi-
cial Norwegian food composition table35 and available 
literature.28 Data for K1 are mostly developed by public 
authorities in Finland,36 Sweden37 and USA.38 For some 
Norwegian food products, analyses were performed using 
high performance liquid chromatography of fermented 
foods.39 K2 was evaluated as one entity with no distinction 
between the different menaquinones. At time of study, 
the most commonly used dietary supplements in Norway 
did not contain vitamin K. Thus, vitamin K intake reflects 
only dietary sources. Measurements used as independent 
variables in this study are the total dietary amount of K1 
and K2, expressed as energy- adjusted residuals.40
health examination and health habits
Baseline examinations included measurements of height, 
weight, waist circumference, resting blood pressure 
(Dinamap 845 XT equipment (Criticon)) and non- fasting 
venous blood samples for evaluation of serum lipids and 
glucose. Serum samples of total cholesterol, HDL choles-
terol, triglycerides and glucose were analysed within 
7 days at the department of Clinical Chemistry, Ullevål 
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reagents from Boehringer Mannheim (Roche, Basel, 
Switzerland).
Information on educational level and medication use 
was collected through self- administered questionnaires.
Hypertension was considered present if the mean of 
at least two consecutive measurements of systolic blood 
pressure was ≥140 mm Hg or of diastolic blood pres-
sure ≥90 mm Hg or if use of medication for hypertension 
was reported.
Diabetes was diagnosed according to diagnostic criteria 
at the time of the screening/survey. Participants taking 
diabetic medications or who reported a diagnosis of 
diabetes were defined as having diabetes mellitus. Also, 
participants with a serum glucose level >7 mmol/L who 
had not eaten a meal during the last 8 hours, or with 
glucose level >11.1 mmol/L and less than 8 hours since 
their last meal, were defined as having diabetes. Pre- 
diabetes was defined as having glucose levels between 
5.6 and 7 mmol/L at least 8 hours after their last meal or 
between 7.8 and 11 mmol/L less than 8 hours after their 
last meal.
Participants answered one categorical question on past- 
year vigorous physical activity resulting in sweating or 
breathlessness (none, <1 h/week, 1–2 h/week, or ≥3 h/
week). This variable was treated as a categorical variable 
with none as the reference.
Participants were classified as non- smokers, former 
smokers or current smokers and this variable was treated 
as a categorical variable with non- smokers as reference.
Outcome
The study endpoints were incident (first time) hospital-
isation with CHD (International classification of diseases 
(ICD)9 codes 410–414, ICD10 codes I20–I25) as primary 
or secondary diagnosis or death with CHD as the under-
lying cause of death. Participants were followed from base-
line through 31 December 2009 for CHD events through 
the Cardiovascular Disease in Norway project database 
(CVDNOR, www. cvdnor. no)41 42 and The Cause of Death 
Registry. Follow- up time represented time from baseline 
(1997–1999) until CHD, death from other causes, emigra-
tion or 31 December 2009, whichever came first. During 
follow- up, there were 107 non- fatal and 5 fatal events of 
interest while 60 participants died due to other causes 
and were censored at date of death.
statistical analyses
Energy- adjusted residuals were obtained from linear 
regression models with total energy intake as indepen-
dent variable and K1 or K2 as dependent variables. The 
residuals measure the difference between actual intake 
and expected intake predicted by total energy intake40 
and thereby provides an assessment of K1 and K2 intake 
relative to energy consumed. Residuals were then catego-
rised into sex- specific quartiles.
Descriptive characteristics included counts with 
percents and medians (interquartile range) for cate-
gorical and continuous variables, respectively. Trends in 
dichotomous, categorical and continuous baseline char-
acteristics across energy- adjusted quartiles of K1 and K2 
were evaluated using logistic, ordinal logistic and linear 
regression analyses, respectively. The median residuals 
for each quartile group was specified as a continuous 
independent variable in the regression models.
Cox proportional hazards models were used to calcu-
late adjusted HR and 95% CIs for CHD associated with 
sex- specific energy- adjusted quartiles and per 10 µg incre-
ments of K1 or K2 intake. The covariates included were 
either those associated with intake of K1 or K2 and with 
CHD, or those that modified the association of either 
K1 or K2 with CHD when included in the multivari-
able model. Analyses included adjustments for sex, age 
(years) and total energy intake (kcal/day) (model 1), 
with additional adjustment for categories of vigorous 
physical activity (none vs <1 hour/week, 1–2 hours/week 
and ≥3 hours/week), smoking habits (previous smokers 
and current smokers, respectively vs non- smokers) and 
education (high school or vocational school, and any 
college or university, respectively vs primary school(≤10 
years)) (model 2). In a third model, K1 was adjusted addi-
tionally for energy- adjusted intake of fibre (g/day) and 
folate (mg/day); K2 was additionally adjusted for energy- 
adjusted intake of saturated fatty acids (SFA)(g/day) 
and calcium (mg/day) (model 3). The following addi-
tional potential confounders were also evaluated but not 
included in the tables as they did not noticeably alter the 
vitamin K1 or K2 coefficients for CHD: family history of 
myocardial infarction and energy- adjusted alcohol intake 
(g/day). Further, adjusting for the following intermediate 
factors: body mass index (BMI, kg/m2), diabetes mellitus 
(pre- diabetes and diabetes, respectively, vs no diabetes), 
hypertension, serum total cholesterol (mmol/L) and 
statin use, only attenuated the association to a small 
degree.
To test for linear trends across energy- adjusted quartiles 
of K1 and K2 intakes, the median value of the residuals 
within each quartile group was entered as a continuous 
independent variable. Supplementary analyses re- evalu-
ated K1 and K2 intake as sex- specific quartiles of absolute 
intake rather than energy- adjusted residuals.
Missing data on physical activity (3.8%), education 
(0.8%) and smoking habits (2.1%) were handled with 
listwise deletion in all analyses included in the main 
manuscript. In supplementary analyses, missing values for 
physical activity, smoking and education were imputed 
using ordinal logistic regression as the imputation model 
in MICE (multiple imputation using chained equation) 
with 20 imputations. All variables in the Cox regression 
models were included as imputation variables together 
with total cholesterol, HDL cholesterol, triglycerides and 
BMI as auxiliary variables due to their correlation with 
physical activity, smoking and education.
The proportional hazards assumption was evaluated 
using Schoenfeld’s test and log–log test.
In Cox regression with penalised splines, the functional 
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residuals) and risk of CHD was estimated by smoothing 
splines, in which the estimated smooth functions were 
used to plot the relative hazards of CHD.43 Intakes above 
the 95th percentile and below the 5th percentile are 
excluded in the figure.
To test for sex interactions between K1 and K2, we 
compared models with and without an interaction term 
using likelihood- ratio test.
Statistical analyses were performed using Stata V.15 
(Stata Corp LP) and R V.3.4.0 (https://www. r- project. 
org/, The R Foundation for Statistical Computing, 
Vienna, Austria). P<0.05 were considered statistically 
significant.
Consent to participate
All subjects gave their written consent to participate in 
the study.
results
Reported intake of energy- adjusted K1 ranged from 8 to 
1063 µg/day/1000 kcal (median 48 µg/day/1000 kcal) 
and were higher for women compared with men. Intake 
of energy- adjusted K2 ranged from 1 to 31 µg/day/1000 
kcal (median 7 µg/day/1000 kcal) and were slightly 
higher for women compared with men.
The major dietary sources of K1 were vegetables (64%), 
fruits and berries (6%) and milk and milk products (6%), 
while sources of K2 were cheese (40%), other dairy prod-
ucts (14%), meat (24%) and eggs (13%).
In the evaluation of baseline characteristics associated 
with K1 intake, the concentration of HDL cholesterol and 
the proportion of participants who were highly educated 
and reported at least 1 hour of vigorous physical activity 
per week were higher with higher quartiles of K1 intake 
(table 1). Further, intakes of energy- adjusted total vitamin 
K, folate and fibre were higher with higher K1 intake 
quartiles. In contrast, a lower proportion with a family 
history of CHD and lower energy- adjusted K2, SFA and 
carbohydrate intakes were noted with higher K1 intake. 
In addition, intake of fruit and berries and vegetables 
were higher with higher K1 intake quartiles, while intake 
of cheese, milk and milk products and soft drinks with 
sugar were lower with higher intake quartiles of energy- 
adjusted K1 intake.
Evaluation of baseline characteristics by quartiles of 
energy- adjusted K2 intake identified that the proportion 
of participants highly educated, and the concentration 
of HDL cholesterol were higher with higher quartiles of 
K2 intake, while the concentration of triglycerides was 
lower (table 2). Further, intake of energy- adjusted total 
fat, SFA and calcium was higher with higher K2 intake 
quartiles. In contrast, lower intake of energy- adjusted K1 
and carbohydrates was noted with higher K2 intake. In 
addition, intake of butter, eggs, cheese, meat and minced 
meat were higher with higher quartiles, while intake of 
soft drinks with sugar and fruit and berries were lower 
with higher quartiles of energy- adjusted K2 intake.
Association between dietary vitamin K1 and ChD
During a mean 10.8 (SD 1.3) years follow- up, representing 
32 362 person years among 2987 participants, we docu-
mented 112 incident CHD events. Due to listwise dele-
tion of missing values (2.1% for smoking habits, 0.8% for 
education and 3.8% for physical activity), multivariable- 
adjusted analyses included 6.5% fewer participants 
compared with model 1 analyses (ie, 2792 (1213 men and 
1579 women) participants and 100 CHD events).
When adjusting for age, sex and total energy intake, 
there was no association between intake of energy- 
adjusted K1 and CHD comparing the fourth to the first 
quartile and there was no trend (table 3, model 1). The 
results were similar when further adjusting for physical 
activity, smoking habits and education (HRQ4vs.Q1=0.92 
(0.54 to 1.57), p for trend 0.64; table 3, model 2). In anal-
yses of energy- adjusted K1 intake as a continuous variable 
(per 10 µg increase), there was no association between K1 
and CHD in the adjusted analysis (table 3, model 2). Addi-
tional adjustments for energy- adjusted fibre and folate 
did not materially change the results (table 3, model 
3). In supplementary analyses, where missing data were 
handled with multiple imputation, results were similar to 
those presented in table 3 (online supplementary table 1, 
models 2 and 3).
Results were consistent with the above analyses in the 
supplemental analyses evaluating sex- specific quartiles of 
absolute K1 intake rather than energy- adjusted residuals 
(online supplementary table 2).
Association between dietary vitamin K2 and ChD
When adjusting for age, sex and total energy intake, 
there was a lower risk of CHD with energy- adjusted K2 
in the fourth compared with the first quartile (HRQ4vs.
Q1=0.50 (0.28 to 0.88), p for trend 0.02; table 3, model 
1). Results were consistent when further adjusting for 
physical activity, smoking habits and education (HRQ4vs.
Q1=0.52 (0.29 to 0.94), p for trend 0.03; table 3, model 
2). Consistency in results was observed in analyses of 
K2 intake as a continuous variable (per 10 µg increase; 
HR=0.74 (0.52 to 1.05), p=0.09). Additional adjustments 
for energy- adjusted SFA and calcium slightly attenuated 
the risk estimates for the association between K2 intake 
and CHD (HRQ4vs.Q1=0.58 (0.28 to 1.19), p for trend 0.16; 
table 3, model 3). Similar results were found in supple-
mentary analyses where missing data were handled with 
multiple imputation (model 2: HR per 10µg increase=0.70 (0.50 
to 0.98), p=0.04) (online supplementary table 1, models 
2 and 3).
When evaluating sex- specific absolute K2 intake rather 
than energy- adjusted residuals, HRs were similar to those 
observed in the primary analyses (HRQ4vs.Q1=0.72 (0.36 
to 1.45), p for trend 0.25; online supplementary table 2, 
model 2). Similarly, the penalised spline figure for abso-
lute K2 intake and its association with CHD adjusting for 
model 2 covariates showed a tendency towards lower risk 
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Table 1 Baseline characteristics by sex- specific quartiles of energy- adjusted residuals of vitamin K1 intake: the Hordaland 
Health Study
Total Q1 Q2 Q3 Q4 P trend*
Subjects, n 2987 746 747 748 746
Age, years 48 (47 to 48) 48 (47 to 48) 48 (47 to 48) 48 (48 to 49) 48 (47 to 49) 0.135
Men 1279 (42.8) 319 (42.8) 320 (42.8) 321 (42.9) 319 (42.8) 0.993
Any college and/or university 
education
1136 (38.3) 265 (36.0) 288 (38.9) 289 (38.8) 294 (39.6) 0.018
Family history of CHD 1183 (40.9) 314 (43.3) 309 (42.6) 286 (39.3) 274 (38.4) 0.034
Smoking habits 0.104
  Previous smokers 914 (31.3) 214 (29.4) 227 (30.8) 237 (32.4) 236 (32.5)
  Current smokers 978 (33.5) 239 (32.8) 231 (31.4) 261 (35.7) 247 (34.0)
Physical activity <0.001
  None 741 (25.8) 198 (27.8) 201 (28.0) 188 (26.0) 154 (21.4)
  <1 hour/week 810 (28.2) 226 (31.7) 192 (26.7) 201 (27.8) 191 (26.5)
  1–2 hours/week 907 (31.6) 207 (29.0) 239 (33.3) 226 (31.3) 235 (32.6)
  ≥3 hours/week 415 (14.4) 82 (11.5) 86 (12.0) 107 (14.8) 140 (19.4)
Hypertension 707 (23.7) 172 (23.1) 176 (23.6) 185 (24.7) 174 (23.3) 0.945
Glucose intolerance 0.875
  Pre- diabetes 66 (2.2) 24 (3.2) 12 (1.6) 14 (1.9) 16 (2.2)
  Diabetes 27 (0.9) 8 (1.1) 4 (0.5) 5 (0.7) 10 (1.4)
Body mass index, kg/m2 24.9 (22.8 to 27.4) 25.0 (22.8 to 27.4) 25.0 (22.8 to 27.6) 24.9 (22.9 to 27.5) 24.7 (22.6 to 27.2) 0.148
Waist circumference, cm 85.0 (77.0 to 94.0) 85.0 (77.0 to 94.0) 85.0 (77.0 to 94.0) 85.0 (77.0 to 93.0) 85.0 (76.0 to 93.0) 0.266
Serum cholesterol, mmol/L 5.65 (5.06 to 6.30) 5.58 (5.05 to 6.25) 5.70 (5.11 to 6.44) 5.66 (5.05 to 6.27) 5.65 (5.03 to 6.25) 0.331
Serum LDL- C, mmol/L 3.56 (3.01 to 4.17) 3.53 (2.98 to 4.14) 3.65 (3.06 to 4.29) 3.56 (3.02 to 4.11) 3.54 (2.94 to 4.10) 0.072
Serum HDL- C, mmol/L 1.28 (1.06 to 1.53) 1.27 (1.04 to 1.52) 1.28 (1.07 to 1.51) 1.27 (1.05 to 1.53) 1.31 (1.07 to 1.58) 0.004
Serum triglycerides, mmol/L 1.40 (1.01 to 2.03) 1.43 (1.01 to 2.02) 1.39 (1.00 to 1.99) 1.39 (1.04 to 2.11) 1.38 (0.98 to 2.05) 0.462
Energy intake, kcal/day 2057 (1690 to 
2550)
2152 (1712 to 2671) 1944 (1608 to 2353) 2032 (1627 to 2485) 2171 (1775 to 2687) <0.001
Dietary intake
  Total vitamin K, µg/day 120 (85 to 175) 78 (58 to 99) 95 (76 to 118) 137 (111 to 161) 234 (189 to 301) <0.001
  Total vitamin K, µg/day/1000 kcal 56 (43 to 79) 36 (31 to 42) 49 (44 to 55) 65 (57 to 76) 105 (84 to 144) <0.001
  Vitamin K2, µg/day 15 (11 to 21) 16 (12 to 22) 14 (11 to 20) 15 (11 to 20) 15 (12 to 20) 0.336
  Vitamin K2, µg/day/1000 kcal 7 (6 to 9) 8 (6 to 9) 7 (6 to 9) 7 (6 to 9) 7 (6 to 9) <0.001
  Vitamin K1, µg/day 103 (69 to 157) 61 (44 to 77) 81 (63 to 101) 121 (99 to 143) 218 (172 to 282) <0.001
  Vitamin K1 µg/day/1000 kcal 48 (35 to 71) 29 (23 to 33) 41 (37 to 47) 58 (50 to 67) 98 (77 to 136) <0.001
  Total fat, E% 32 (29 to 36) 32 (28 to 35) 33 (29 to 36) 33 (30 to 37) 33 (29 to 36) <0.001
  SFA, E% 13 (11 to 14) 13 (11 to 14) 13 (11 to 14) 13 (11 to 14) 12 (11 to 14) 0.004
  PUFA, E% 7 (6 to 8) 6 (5 to 7) 7 (6 to 8) 7 (6 to 9) 7 (6 to 9) <0.001
  MUFA, E% 10 (9 to 12) 10 (9 to 11) 10 (9 to 12) 11 (9 to 12) 10 (9 to 12) 0.357
  Protein, E% 16 (14 to 17) 16 (14 to 17) 16 (14 to 17) 16 (14 to 17) 16 (15 to 18) <0.001
  Carbohydrates, E% 49 (46 to 53) 50 (47 to 54) 50 (46 to 53) 49 (45 to 52) 48 (45 to 52) <0.001
  Alcohol, E% 1 (0 to 3) 1 (0 to 3) 1 (0 to 3) 2 (0 to 3) 2 (1 to 3) 0.001
  Folate, µg/day/1000 kcal 110 (95 to 133) 99 (88 to 113) 105 (93 to 121) 112 (98 to 131) 135 (113 to 164) <0.001
  Fibre, g/day/1000 kcal 11 (10 to 13) 10 (9 to 12) 11 (10 to 13) 11 (10 to 13) 13 (11 to 16) <0.001
Intake of food items, g/day/1000 kcal
  Butter† 0 (1.2) 0 (1.3) 0 (1.1) 0 (1.1) 0 (1.2) 0.749
  Margarine 3 (2 to 8) 2 (1 to 3) 3 (2 to 8) 3 (2 to 11) 3 (2 to 9) <0.001
  Cheese 13 (7 to 21) 15 (8 to 24) 13 (7 to 22) 12 (7 to 19) 12 (6 to 20) <0.001
  Yoghurt 5 (0 to 18) 6 (0 to 21) 5 (0 to 16) 6 (0 to 18) 5 (0 to 17) 0.740
  Milk and milk products 129 (65 to 205) 157 (86 to 230) 134 (71 to 220) 127 (57 to 193) 105 (51 to 174) <0.001
  Sausages 20 (2 to 49) 17 (1 to 47) 18 (1 to 47) 21 (4 to 53) 21 (5 to 53) 0.067
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Total Q1 Q2 Q3 Q4 P trend*
  Minced meat 24 (16 to 34) 25 (15 to 35) 25 (16 to 35) 25 (16 to 34) 22 (14 to 31) <0.001
  Soft drinks with sugar 25 (0 to 65) 31 (3 to 76) 28 (2 to 69) 24 (0 to 61) 18 (0 to 51) <0.001
  Fruit and berries 104 (65 to 154) 91 (56 to 132) 103 (67 to 150) 105 (68 to 167) 114 (71 to 164) <0.001
  Vegetables 85 (54 to 131) 49 (35 to 72) 74 (53 to 101) 98 (67 to 134) 154 (104 to 212) <0.001
Values are presented as N (%) and median (interquartile range) for continuous and categorical data, respectively.
*Logistic regression for dichotomous categories, ordered logistic regression when more than two categories and linear regression for continuous variables where median residuals 
within each quartile group was used as the independent variable in the analyses.
†Mean (median) are reported due to a large proportion with zero intake.
CHD, coronary heart disease; E%, energy per cent; HDL- C, high- density lipoprotein cholesterol; LDL- C, low- density lipoprotein cholesterol; MUFA, monounsaturated fatty acids; 
PUFA, polyunsaturated fatty acids; Q, quartile; SFA, saturated fatty acids.
Table 1 Continued
DIsCussIOn
Among community- dwelling middle- age adults in Western 
Norway, a higher energy- adjusted reported intake of 
K2 was associated with a lower risk of subsequent CHD 
events, whereas intake of K1 was not associated with inci-
dent CHD. Similar direction of associations was observed 
when further adjusting for potential dietary confounders.
strengths and weaknesses
Strengths of our study include a long follow- up time with 
minimal competing risk from other causes of death in 
this relatively young study population. Linkage to the 
CVDNOR project database assured complete follow- up. 
In addition, we had information on several possible 
confounders including baseline health status, medication 
use, health habits and history of CHD which enabled us 
to evaluate incident CHD.
Weaknesses include self- reported information on 
dietary intake, health habits and medication use which 
may lead to misclassification in covariates used in the 
analyses. Furthermore, we lack information on changes 
in diet including intake of vitamin K, medications and 
risk factors over time. Inherent problems with FFQs are 
systematic under- reporting and over- reporting. However, 
the FFQ is well suited to rank individuals when adjusting 
for total energy intake.44 This FFQ is not validated specif-
ically for intake of vitamin K. Vitamin K content of foods 
differs according to production conditions, and the 
bioavailability is dependent on preparation, fat content of 
meals, the food matrix and subtypes of vitamin K. There-
fore, although the rank ordering of participants may be 
valid, the absolute vitamin K intake based on FFQ is likely 
inaccurate.5 29 30 45 46 In addition, K2 can be produced 
by intestinal gut microbiota, but little is known about 
its contribution to vitamin K status since the majority is 
located in bacterial membranes in the colon and is prob-
ably not available for absorption.26
Further, vitamin K2 intake may be underestimated in 
this study population since much of the information on 
vitamin K content of food used in this study comes from 
a Dutch study,28 and recent research have shown that 
Norwegian cheeses are especially rich in vitamin K2.29 47 
In addition, we could not differentiate the subtypes of 
vitamin K219 in our study.
Although we performed multivariable analyses, residual 
confounding may still be present.
results in relation to other studies
This study did not find an association between intake 
of K1 and CHD, in line with results from most previous 
studies.19 20 22 23 However, Erkkilä et al concluded that 
high K1 intake may be a marker of low CHD risk, but that 
dietary patterns associated with K1 intakes, rather than 
intake of K1 itself might account for this association.21 
Similarly, Juanola- Falgarona et al studied the association 
between dietary K1 and K2 with mortality in a cohort with 
high cardiovascular disease (CVD) risk, and found that an 
increase in dietary intakes of both K1 and K2 were associ-
ated with a reduced risk of all- cause mortality, while only 
K1 was associated with a reduced risk of CVD mortality.24 
However, since participants came from a Mediterranean 
country in which the consumption of fruit, vegetables 
and vegetable oils was quite high, K1 could be regarded 
as a marker of adherence to a healthy diet.24
Regarding vitamin K2, Geleijnse et al found a 41% lower 
risk of CHD comparing the highest with the lowest tertile 
of K2 intake in the Rotterdam study,20 similar to our 
results. Gast et al found a dose–response relationship with 
a 9% lower CHD risk with each 10 µg higher K2 intake, 
with the strongest association shown for long- chain K2.19 
Opposite from this study where the association atten-
uated when further adjusting for SFA and calcium, the 
association became stronger in both these studies in their 
multivariable models.19 20 Adjusting for SFA and calcium, 
however, may be an overadjustment as dairy products 
rich in SFA and calcium are also major sources of K2.24 
Zwakenberg et al found that only intake of long- chain K2 
(per10µg) was borderline significantly inversely associated 
with CHD mortality (p for trend 0.06).23 This discrepancy 
compared with our study may be because lifestyle factors 
such as diet may have a larger impact on total CHD events 
(fatal and non- fatal) given the underlying mechanisms of 
reducing calcification. Treatment, however, is probably of 
larger importance for CHD mortality.48
In the western diet, cheese is the most important source 
of long- chain K2, and hard cheese is, in general, richer 
in K2 than soft cheese.28 29 Fu et al showed that vitamin K 
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Table 2 Baseline characteristics by sex- specific quartiles of energy- adjusted residuals of vitamin K2 intake: the Hordaland 
Health Study
Total Q1 Q2 Q3 Q4 P trend*
Subjects, n 2987 746 747 747 747
Age, years 48 (47 to 48) 48 (47 to 49) 48 (47 to 48) 48 (47 to 49) 48 (47 to 48) 0.600
Men 1279 (42.8) 319 (42.8) 320 (42.8) 320 (42.8) 320 (42.8) 0.977
Any college and/or university 
education
1136 (38.3) 261 (35.3) 272 (36.8) 284 (38.3) 319 (42.9) 0.001
Family history of CHD 1183 (40.9) 292 (40.7) 308 (42.1) 284 (39.3) 299 (41.6) 0.904
Smoking habits 0.267
  Previous smokers 914 (31.3) 217 (29.7) 241 (33.1) 229 (31.2) 227 (31.1)
  Current smokers 978 (33.5) 239 (32.7) 244 (33.5) 240 (32.7) 255 (34.9)
Physical activity 0.114
  None 741 (25.8) 185 (25.8) 181 (25.5) 194 (26.9) 181 (25.0)
  <1 hour/week 810 (28.2) 189 (26.3) 179 (25.2) 224 (31.0) 218 (30.2)
  1–2 hours/week 907 (31.6) 214 (29.8) 244 (34.4) 224 (31.0) 225 (31.1)
  ≥3 hours/week 415 (14.4) 130 (18.1) 106 (14.9) 80 (11.1) 99 (13.7)
Hypertension 707 (23.7) 185 (24.8) 180 (24.1) 184 (24.6) 158 (21.2) 0.100
Glucose intolerance 0.543
  Pre- diabetes 66 (2.2) 18 (2.4) 15 (2.0) 17 (2.3) 16 (2.2)
  Diabetes 27 (0.9) 6 (0.8) 7 (0.9) 2 (0.3) 12 (1.6)
Body mass index, kg/m2 24.9 (22.8 to 27.4) 24.8 (22.7 to 27.4) 25.1 (23.0 to 27.5) 25.0 (22.9 to 27.3) 24.8 (22.6 to 27.4) 0.830
Waist circumference, cm 85 (77 to 94) 84 (77 to 93) 85 (77 to 94) 85 (77 to 94) 85 (76 to 93) 0.724
Serum cholesterol, mmol/L 5.65 (5.06 to 6.30) 5.66 (5.02 to 6.30) 5.64 (5.07 to 6.36) 5.7 (5.1 to 6.32) 5.57 (5.05 to 6.20) 0.124
Serum LDL- C, mmol/L 3.56 (3.01 to 4.17) 3.57 (3.00 to 4.14) 3.58 (2.99 to 4.19) 3.60 (3.07 to 4.24) 3.52 (2.97 to 4.09) 0.227
Serum HDL- C, mmol/L 1.28 (1.06 to 1.53) 1.27 (1.03 to 1.52) 1.27 (1.07 to 1.54) 1.30 (1.06 to 1.55) 1.30 (1.06 to 1.54) 0.043
Serum triglycerides, mmol/L 1.40 (1.01 to 2.03) 1.44 (1.04 to 2.16) 1.40 (1.00 to 2.05) 1.39 (1.01 to 1.99) 1.36 (0.97 to 1.96) 0.022
Energy intake, kcal/day 2057 (1690 to 2550) 2098 (1682 to 2645) 1976 (1603 to 2398) 2014 (1653 to 2469) 2215 (1795 to 2637) 0.002
Dietary intake
  Total vitamin K, µg/day 120 (85 to 175) 119 (82 to 179) 116 (78 to 169) 114 (83 to 165) 133 (94 to 186) 0.728
  Total vitamin K, µg/day/1000 
kcal
56 (43 to 79) 56 (40 to 80) 55 (42 to 81) 55 (43 to 76) 59 (46 to 80) 0.011
  Vitamin K2, µg/day 15 (11 to 21) 10 (8 to 13) 13 (11 to 16) 16 (14 to 19) 24 (21 to 29) <0.001
  Vitamin K2, µg/day/1000 kcal 7 (6 to 9) 5 (4 to 5) 7 (6 to 7) 8 (8 to 9) 11 (10 to 13) <0.001
  Vitamin K1, µg/day 103 (69 to 157) 109 (72 to 167) 101 (67 to 155) 97 (67 to 149) 104 (71 to 156) 0.329
  Vitamin K1, µg/day/1000 kcal 48 (35 to 71) 51 (36 to 78) 49 (35 to 74) 46 (35 to 67) 47 (34 to 68) 0.038
  Total fat, E% 32 (29 to 36) 30 (27 to 34) 31 (29 to 35) 33 (30 to 36) 35 (32 to 38) <0.001
  SFA, E% 13 (11 to 14) 11 (19 to 12) 12 (11 to 13) 13 (12 to 14) 14 (13 to 16) <0.001
  PUFA, E% 7 (6 to 8) 7 (6 to 9) 7 (6 to 8) 7 (6 to 8) 6 (6 to 8) <0.001
  MUFA, E% 10 (9 to 12) 10 (8 to 11) 10 (9 to 11) 11 (10 to 12) 11 (10 to 12) <0.001
  Protein, E% 16 (14 to 17) 15 (13 to 16) 16 (14 to 17) 16 (15 to 17) 16 (15 to 18) <0.001
  Carbohydrates, E% 49 (46 to 53) 53 (49 to 57) 50 (47 to 53) 48 (45 to 51) 46 (43 to 49) <0.001
  Alcohol, E% 1 (0 to 3) 1 (0 to 3) 1 (0 to 3) 1 (0 to 3) 1 (0 to 3) 0.387
  Calcium, mg/day/1000 kcal 385 (313 to 468) 332 (264 to 410) 373 (302 to 448) 389 (329 to 464) 443 (374 to 538) <0.001
  Fibre, g/day/1000 kcal 11 (10 to 13) 12 (11 to 15) 12 (10 to 13) 11 (9 to 13) 11 (9 to 12) <0.001
Intake of food items, g/
day/1000 kcal
  Butter† 0 (1.2) 0 (0.5) 0 (1.0) 0 (1.3) 0 (1.9) <0.001
  Margarine 3 (2 to 8) 3 (2 to 10) 3 (2 to 7) 3 (2 to 8) 3 (2 to 5) <0.001
  Egg 8 (4 to 11) 5 (3 to 8) 8 (5 to 11) 8 (5 to 12) 8 (4 to 11) <0.001
  Cheese 13 (7 to 21) 7 (3 to 12) 10 (6 to 15) 14 (9 to 20) 25 (17 to 34) <0.001
  Yoghurt 5 (0 to 18) 4 (0 to 15) 5 (0 to 17) 6 (0 to 19) 5 (0 to 19) 0.456
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Total Q1 Q2 Q3 Q4 P trend*
  Sausage 20 (2 to 49) 21 (2 to 53) 22 (3 to 53) 21 (3 to 50) 17 (2 to 42) <0.001
  Meat 55 (41 to 70) 47 (33 to 58) 56 (43 to 71) 61 (46 to 77) 58 (42 to 76) <0.001
  Minced meat 24 (16 to 34) 19 (12 to 28) 24 (16 to 33) 27 (18 to 37) 27 (17 to 36) <0.001
  Soft drinks with sugar 25 (0 to 65) 29 (1 to 72) 26 (0 to 66) 26 (2 to 64) 23 (0 to 54) <0.001
  Fruit and berries 104 (65 to 154) 116 (74 to 174) 105 (67 to 162) 100 (64 to 149) 93 (57 to 135) <0.001
  Vegetables 85 (54 to 131) 85 (50 to 133) 90 (58 to 139) 82 (55 to 125) 84 (53 to 122) 0.006
Values are presented as N(%) and median (interquartile range) for categorical and continuous variables, respectively.
*Logistic regression for dichotomous categories, ordered logistic regression when more than two categories and linear regression for continuous variables where median residuals 
within each quartile group was used as the independent variable in the analyses.
†Mean (median) are reported due to a large proportion with zero intake.
CHD, coronary heart disease; E%, energy per cent; HDL- C, high- density lipoprotein cholesterol; LDL- C, low- density lipoprotein cholesterol; MUFA, monounsaturated fatty acids; 
PUFA, polyunsaturated fatty acids; Q, quartile; SFA, saturated fatty acids.
Table 2 Continued
















Q1 63 (25) 746 33 (4.4) 1 (ref) 1 (ref) 1 (ref)
Q2 83 (27) 747 18 (2.4) 0.47 (0.27 to 0.85) 0.50 (0.27 to 0.93) 0.48 (0.26 to 0.89)
Q3 122 (32) 748 31 (4.1) 0.84 (0.51 to 1.39) 0.89 (0.53 to 1.51) 0.83 (0.49 to 1.41)
Q4 269 (191) 746 30 (4.0) 0.91 (0.55 to 1.49) 0.92 (0.54 to 1.57) 0.69 (0.38 to 1.27)
P for trend** 0.64 0.64 0.59
Continuous, per 
10 µg
1.00 (0.99 to 1.02),
p=0.57
1.00 (0.99 to 1.02),
p=0.62




Q1 10 (4) 746 35 (4.7) 1 (ref) 1 (ref) 1 (ref)
Q2 13 (4) 747 30 (4.0) 0.79 (0.48 to 1.29) 0.79 (0.47 to 1.34) 0.83 (0.49 to 1.43)
Q3 17 (4) 747 29 (3.9) 0.77 (0.47 to 1.26) 0.77 (0.45 to 1.31) 0.84 (0.47 to 1.48)
Q4 26 (8) 747 18 (2.4) 0.50 (0.28 to 0.88) 0.52 (0.29 to 0.94) 0.58 (0.28 to 1.19)
P for trend** 0.02 0.03 0.16
Continuous, per 
10 µg
0.71 (0.50 to 0.99),
p=0.04
0.74 (0.52 to 1.05),
p=0.09
0.82 (0.51 to 1.30),
p=0.39
Sex- specific quartiles with 1279 men and 1708 women. The Hordaland Health Study.
*HR are presented as Q2 versus Q1, Q3 versus Q1, Q4 versus Q1.
†Cox proportional hazards regression analysis adjusted for age, sex and total energy intake.
‡Adjusted in addition for physical activity, smoking habits and education.
§Analyses were based on a reduced number of participants (n=2792) and CHD events (n=100) due to listwise deletion when covariates were missing.
¶Vitamin K1 is adjusted in addition for energy- adjusted fibre and folate, while vitamin K2 is adjusted in addition for energy- adjusted calcium and 
saturated fatty acids.
**P trend, to test for linear trends across quartiles, we modelled the median intake of each quartile as a continuous variable.
N, number of participants; Q, quartile.
100 g, and that reduced- fat products contained 5%–22% 
of the vitamin K found in full- fat equivalents.30 K2 in 
cheese originates from bacterial processes present at the 
start of the cheese- making process.26 As different lactic 
acid bacteria are used in cheese making, a large variability 
in K2 content is found. Cheeses from Norway are among 
those with the highest long- chain K2 content.29 47
A meta- analysis including only two published studies of 
sufficient quality did not conclude that there is a lower 
risk of cardiovascular events with higher intake of K2.49 
However, a systematic review and meta- analysis found that 
supplementation with vitamin K (K1 and K2) significantly 
reduced vascular calcification, but not vascular stiffness, 
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Figure 1 Cox proportional hazards regression with 
penalised splines, The Hordaland Health Study. Distribution 
of partial HR (solid line) with 95% CI (shadow) for coronary 
heart disease across the distribution of dietary vitamin K2 
in μg per day (not energy- adjusted residuals). The model 
includes adjustment for age, sex, total energy intake, physical 
activity, smoking habits and education. Intakes above the 
95th percentile and below the 5th percentile are excluded in 
the figure.
supplementation with K1 on coronary artery calcifica-
tion progression in older men and women and found no 
difference between the control and treatment groups in 
the main analyses. Less progression of coronary artery 
calcification was found in participants who were ≥85% 
adherent to supplementation and in those with pre- 
existing coronary artery calcification.51
Potential mechanisms
The lower risk of CHD with a high intake of K2 may have 
different explanations. Jakobsen et al showed that intake 
of SFA seems to be preferable compared with intake of 
carbohydrates with high glycaemic index in order to 
reduce risk of myocardial infarction.52 Further, intake 
of K2 correlates positively with intake of SFA, especially 
dairy sources as cheese, and negatively with intake of 
carbohydrates, especially sugar- rich sources as soft drinks 
with sugar and fruit and berries (both fresh and canned). 
Further, cheese has been associated with lower risk of 
CHD,53 and the median intake of cheese more than 
triples between the first and fourth quartile of K2 intake. 
This may also partly explain why adjusting for SFA and 
calcium attenuated the association between intake of K2 
and CHD (table 3, model 3).
The lower risk of CHD with a high intake of K2 may 
further be explained by carboxylation of vascular Matrix 
Gla Protein and consequently less arterial calcification.54 
Intimal calcification starts in the inner layer of large 
arteries, is associated with dyslipidaemia and may cause 
ischemia and arterial infarction, while calcification of the 
medial layer occurs even in small arteries and may lead to 
arterial stiffness, hypertension and left ventricular hyper-
trophy that further increases risk of CHD.55
The observed association for K2 only may be due to the 
fact that in addition to being cleared by the liver, it is also 
transported to extrahepatic tissues.5 However, extrahe-
patic vitamin K- dependent proteins seem to be of lower 
priority compared with those in the liver.26 27 Thus, one 
hypothesis is that intake of vitamin K has to be of a certain 
magnitude in order to have an effect on CHD. The 
different results on K1 and K2 may also be due to biolog-
ical differences between K1 and K2 or to lower ability of 
the FFQ to estimate K1.4 26 56 Due to different bioavail-
ability, the contribution of K2 to vitamin K status is at least 
equal to that of K1 even though dietary K1 contributes to 
the majority of the total vitamin K intake.26 46 57
Alternatively, our findings may reflect that K2 may be a 
marker of another nutrient or food constituent that has 
heart- healthy properties.
Implications and future research
Our findings contribute to the sparse literature relating 
dietary vitamin K to future CHD risk. Current dietary 
guidelines are based on insufficient knowledge with 
regard to vitamin K metabolism and the different char-
acteristics of K1 and K2. Therefore, our results indicate a 
need for more studies on the association between K2 and 
CHD. In addition, more knowledge about the absorption, 
transport and bioactivity of K2 is warranted.
Conclusion
In this Norwegian community- based study population, we 
observed that intake of K2 was associated with lower risk 
of CHD, while there was no association between intake of 
K1 and CHD. These results are considered generalisable 
to other middle- aged Western populations in which dairy 
products are the primary source of K2.
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